- Greeks Head to Brussels With Incomplete Bailout Deal
- Will Accelerating Inflation End China Stock Market Rally?
- How Big Will the ECB’s Next Liquidity Injection Be?
- Rio Tinto Dividend Surprise Masks Aluminum Hit
- ECB to Leave Rates Unchanged Ahead of More Loans
- Traders to Watch Jobless Claims for Signs of Recovery
- China Says Yuan Rise Not Due to Xi's Washington Visit
- BoE Set for More Stimulus to Shore up Recovery
- Top Soccer Teams in Europe by Revenue
MOST SHARED
- Credit Suisse Swings to Loss, Sees Good 2012 Start
- Rio Tinto Second-Half Profit Down, but Hikes Dividend
- Airbus A380 Wing Checks Extended to Entire Fleet
- Will Accelerating Inflation End China Stock Rally?
- FTSE, DAX and CAC Set to Edge Up On Hopes of Greek Deal
- How to Date a Wall Street Man
- Greek Minister Heads to Brussels With Incomplete Bailout Deal
- W Hotels 'Fashion Next' Partnership to Hit the Runway
- Top Soccer Teams in Europe by Revenue
- Jim Rogers: I Would Not Buy Facebook
MOST POPULAR
HOT ON FACEBOOK
Roche May Have to Boost Genentech Bid
Text Size 
Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.
Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA
Loading...
()
], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.
"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."
A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.
"In the end it could make sense, but of course that all depends on the price," Kulhoff said.
RELATED LINKS
It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.
Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.
"That could be the start of a bigger M&A wave," she added.
Data is a real-time snapshot *Data is delayed at least 15 minutes
